Danhong Injection in the Treatment of Acute Ischemic Stroke
This study is currently recruiting participants.
Verified June 2013 by China Academy of Chinese Medical Sciences
Sponsor:
China Academy of Chinese Medical Sciences
Collaborator:
China: State Food and Drug Administration
Information provided by (Responsible Party):
Zhong Wang, China Academy of Chinese Medical Sciences
ClinicalTrials.gov Identifier:
NCT01677208
First received: August 29, 2012
Last updated: June 9, 2013
Last verified: June 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether Danhong injection is effective in the treatment of acute ischemic stroke.
| Condition | Intervention | Phase |
|---|---|---|
|
Acute Stroke |
Drug: Danhong injection Procedure: Standard medical care Drug: placebo |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Randomized, Multi-center, Double-blind, Placebo-controlled Trial of Danhong Injection in the Treatment of Acute Ischemic Stroke |
Further study details as provided by China Academy of Chinese Medical Sciences:
Primary Outcome Measures:
- Modified Rankin Scale 0-1 (favourable outcome) at Day 90 [ Time Frame: Day 90 ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- The Score of effect on symptoms of "Xueyue Zheng"(Blood Stasis syndrome) [ Time Frame: Day 0, Day7, Day 14, Day 30, Day 60, Day 90 ] [ Designated as safety issue: No ]
- Barthel Index score ≥90 [ Time Frame: Day 0, Day7, Day 14, Day 30, Day 60, Day 90 ] [ Designated as safety issue: No ]
- NIH stroke scale(NIHSS) [ Time Frame: Day 0, Day7, Day 14, Day 30, Day 60, Day 90 ] [ Designated as safety issue: No ]The improvement of the NIHSS score ≥4 or the NIHSS score of 0 to 1
- EQ-5D scale [ Time Frame: Day 0, Day 7, Day 14, Day 30, Day 60, Day 90 ] [ Designated as safety issue: No ]
- Global disability on mRS at Day 90. [ Time Frame: Day 90 ] [ Designated as safety issue: No ]The proportion of patients with mRS ≥3 at Day 90.
- Incidence of new-onset major vascular events in 90 days [ Time Frame: Day 90 ] [ Designated as safety issue: Yes ]Major adverse vascular events include ischemic stroke, hemorrhagic stroke, TIA, myocardial infarction and vascular-related death.
- Overall mortality at day 90 [ Time Frame: Day 90 ] [ Designated as safety issue: Yes ]
- Incidence of severe hemorrhages in 90 days [ Time Frame: Day 90 ] [ Designated as safety issue: Yes ]The definition of "Severe hemorrhages" is in accordance with the GUSTO bleeding criteria, including fatal intracranial hemorrhage (ICH), symptomatic intracerebral hemorrhage (sICH) or which could result in substantial hemodynamic compromise requiring treatment.
- Incidence of moderate hemorrhages in 90 days [ Time Frame: Day 90 ] [ Designated as safety issue: Yes ]The definition of "moderate hemorrhages" is in accordance with the GUSTO bleeding criteria, which requires blood transfusion but not results in hemodynamic compromise.
- Documentation of adverse events (AEs) and serious AEs [ Time Frame: 90 days ] [ Designated as safety issue: Yes ]
Other Outcome Measures:
- The changes on the profiles of micro-RNA in 96 patients selected from certain centers [ Time Frame: Day 0, Day 14, Day 90 ] [ Designated as safety issue: Yes ]
- The changes on the expression profiles of mRNA in 96 patients selected from certain centers [ Time Frame: Day 0, Day 14, Day 90 ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 846 |
| Study Start Date: | December 2012 |
| Estimated Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Danhong injection
Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
|
Drug: Danhong injection
A kind of injection made from two kind of Chinese herbs: Salvia miltiorrhiza and Safflower. 40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
Procedure: Standard medical care
Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
|
|
Placebo Comparator: placebo
Based on the standard medical care, 40ml of 0.9% saline as the placebo, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
|
Procedure: Standard medical care
Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
Drug: placebo
0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
|
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Female or male inpatients
- Age: 18 - 70 years.
- Clinical diagnosis of ischemic stroke causing a measurable neurological deficit defined as impairment of language, motor function, cognition and/or gaze, vision or neglect. Ischemic stroke is defined as an event characterized by the sudden onset of an acute focal neurologic deficit presumed to be due to cerebral ischemia after CT scan excludes hemorrhage.
- Clinical diagnosis of "Xueyu Zheng" (Blood Stasis Syndrome) as the scores of Chinese medicine symptoms scales of "Xueyu Zheng" in ischemic stroke ≥ 20. The Chinese medicine symptoms scales of "Xueyu Zheng" is defined as following (1)hemiplegia-10,(2)numbness of limbs-10,(3) dark face-9,(4)purple or dark lip-8,(5)Roughness of skin-4, (6) pain with fixed point-5, (7) purple or dark tongue-10,(8)ecchymosis on tongue-10,(9)purple sublingual vessel-10,(10)varicose sublingual vessel-8,(11)unsmooth pulse-8,(12)intermittent pulse-1.
- Onset of symptoms in 1 week prior to initiation of administration of study drug.
- Clinical diagnosis of cerebral anterior circulation obstruction.
- 4≤NIHSS<20.
- Patient is willing to participate voluntarily and to sign a written patient informed consent. Informed consent will be obtained from each patient or the subject's legally authorized representative or relatives, or deferred where applicable, according to the regulatory and legal requirements of the participating centers.
Exclusion Criteria:
- Evidence of intracranial hemorrhage (ICH) or other cerebral diseases (eg.vascular malformation, tumor, abscess or multiple sclerosis etc.)on the CT-or MRI-scan.
- Patients with thrombolysis or endovascular treatment.
- Known history of allergy or suspected allergic to the drug.
- Blood glucose 2.8 or > 16.8 mmol / l under the treatment of diabetes or with severe complications due to diabetes (eg. peripheral neuropathy, diabetic gangrene).
- Liver function impairment with the value of ALT or AST over 1.5-fold of normal value.
- Renal dysfunction with the value of serum creatinine over 1.5-fold of normal value.
- Severe cardiac dysfunction on echocardiogram or the grade of heart function over Ⅲ grade.
- History of prior stroke with mRS ≥2.
- Complicated with atrial fibrillation.
- Severe stroke as assessed by appropriate imaging techniques (eg. massive cerebral infarction including more than one lobe of brain or over 1/3 of blood-supply area of middle cerebral artery).
- Prior disable patients.
- Hemorrhagic tendency or recent severe or dangerous bleeding in 3 months.
- Suspected addicted into alcohol or drug abuse.
- With severe complications that would make the condition more complicated assessed by the investigator.
- Woman with pregnancy, lactation or positive result of pregnancy test, or women who want to be pregnant in recent 6 months.
- Woman who is under menstrual period.
- Patient who is participating in other trials or has been participated in other trials in recent 3 months.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01677208
Contacts
| Contact: Zhong Wang, Professor | 8610-64014411 ext 3308 | zhonw@vip.sina.com |
| Contact: Jun Liu, Ph.D. | 8610-64014411 ext 2805 | franlj1104@yahoo.com.cn |
Locations
| China, Henan | |
| The First Affiliated Hospital of Henan University of T.C.M. | Recruiting |
| Zhengzhou, Henan, China, 450000 | |
| Contact: Xin-zhi Wang, Professor 86371-66201040 znqznq@163.com | |
| Principal Investigator: Xin-zhi Wang, Professor | |
| China, Hubei | |
| Zhongnan Hospital of Wuhan University | Not yet recruiting |
| Wuhan, Hubei, China, 430030 | |
| Contact: Yu-min Liu, M.D. 8627-67813086 | |
| Principal Investigator: Yu-min Liu, M.D. | |
| Renmin Hospital of Wuhan University | Not yet recruiting |
| Wuhan, Hubei, China, 430060 | |
| Contact: Zhao-hui Zhang, M.D. 8627-88041919 ext 82143 | |
| Principal Investigator: Zhao-hui Zhang, M.D. | |
| China, Hunan | |
| Changsha Central Hospital | Not yet recruiting |
| Changsha, Hunan, China, 410004 | |
| Contact: Zhu-xin Liu, Professor 86-13975128927 | |
| Principal Investigator: Zhu-xin Liu, Professor | |
| Xiangya Hospital Central-south University | Not yet recruiting |
| Changsha, Hunan, China, 410008 | |
| Contact: Xiao-su Yang, M.D. 86731-84327130 sjnk_xy@yahoo.com.cn | |
| Principal Investigator: Xiao-su Yang, M.D. | |
| China, Jiangsu | |
| Nanjing Hospital of T.C.M. | Not yet recruiting |
| Nanjing, Jiangsu, China, 210001 | |
| Contact: Shu-ping Cao, Professor 86-13951014652 | |
| Principal Investigator: Shu-ping Cao, Professor | |
| China, Jilin | |
| The Second Hospital of Jilin University | Active, not recruiting |
| Changchun, Jilin, China, 130041 | |
| China, Liaoning | |
| Affiliated Zhongshan Hospital of Dalian University | Recruiting |
| Dalian, Liaoning, China, 116001 | |
| Contact: Qiang Ma, Professor 86411-62893581 mqiang2100@yahoo.com.cn | |
| Principal Investigator: Qiang Ma, Professor | |
| China, Shanxi | |
| The First Affiliated Hospital to Shanxi Medical University | Not yet recruiting |
| Taiyuan, Shanxi, China, 030001 | |
| Contact: Xiao-yuan Niu, Professor 86-13303467183 | |
| Principal Investigator: Xiao-yuan Niu, Professor | |
| The Second Affiliated Hospital to Shanxi Medical University | Not yet recruiting |
| Taiyuan, Shanxi, China, 030001 | |
| Contact: Guang-lai Li, Professor 86-13703587193 | |
| Principal Investigator: Guang-lai Li, Professor | |
| The PLA Fourth Fifty-one Hospital | Not yet recruiting |
| Xi'an, Shanxi, China, 710054 | |
| Contact: Li-yi Chi, Professor 1173319088@qq.com | |
| Principal Investigator: Li-yi Chi, Professor | |
| Shanxi Province Hospital of T.C.M. | Not yet recruiting |
| Xi'an, Shanxi, China, 710003 | |
| Contact: Zu-cheng Han, Professor 13759968645@139.com | |
| Principal Investigator: Zu-cheng Han, Professor | |
| Shanxi Provincial People's Hospital | Not yet recruiting |
| Xi'an, Shanxi, China, 710068 | |
| Contact: Qian Yang, Professor YangQdoctor@163.com | |
| Principal Investigator: Qian Yang, Professor | |
| Affiliated Hospital of Shanxi University of Chinese Medicine | Not yet recruiting |
| Xianyang, Shanxi, China, 712000 | |
| Contact: Yong-mei Yan, Professor 86-13609216551 | |
| Principal Investigator: Yong-mei Yan, Professor | |
| China, Tianjin | |
| First Teaching Hospital of Tianjin University of Traditional Chinese Medicine | Recruiting |
| Tianjin, Tianjin, China, 300193 | |
| Contact: Zhi-hong Meng, M.D. 86-18722699933 | |
| Principal Investigator: Zhi-hong Meng, M.D. | |
| China | |
| Peking University People's Hospital | Not yet recruiting |
| Beijing, China, 100044 | |
| Contact: Xu-guang Gao, M.D. 8610-88326808 gxg56@tom.com | |
| Principal Investigator: Xu-guang Gao, M.D. | |
| Xuan Wu Hospital Affiliated to Capital Medical University | Active, not recruiting |
| Beijing, China, 100053 | |
| Peking University First Hospital | Recruiting |
| Beijing, China, 100034 | |
| Contact: Xue-zhi Zhang, Professor 010-83572634 zhang.xuezhi@263.net | |
| Principal Investigator: Xue-zhi Zhang | |
| Tiantan Hospital Affiliated to Capital Medical University | Recruiting |
| Beijing, China, 100050 | |
| Contact: Xing-quan Zhao, M.D. 010-67098891 zxq@vip.163.com | |
| Principal Investigator: Xing-quan Zhao, M.D. | |
| Second Artillery General Hospital of People's Liberation Army | Recruiting |
| Beijing, China | |
| Contact: Lei Wang, Professor 8610-66343392 hellowanglei068@163.com | |
| Principal Investigator: Lei Wang | |
Sponsors and Collaborators
China Academy of Chinese Medical Sciences
China: State Food and Drug Administration
Investigators
| Principal Investigator: | Zhong Wang, Professor | Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences |
| Principal Investigator: | Xing-quan Zhao, Professor | Beijing Tiantan Hospital Affiliated to Capital Medical University |
| Study Chair: | Yong-yan Wang, Professor | Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences |
| Study Director: | Xiao-xi Du, Professor | China: State Food and Drug Administration |
More Information
No publications provided
| Responsible Party: | Zhong Wang, Professor, China Academy of Chinese Medical Sciences |
| ClinicalTrials.gov Identifier: | NCT01677208 History of Changes |
| Other Study ID Numbers: | DH20120423 |
| Study First Received: | August 29, 2012 |
| Last Updated: | June 9, 2013 |
| Health Authority: | China: Ministry of Science and Technology |
Keywords provided by China Academy of Chinese Medical Sciences:
|
Acute Ischemic Stroke Randomized Controlled Trial Traditional Chinese Medicine |
Additional relevant MeSH terms:
|
Stroke Cerebral Infarction Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Vascular Diseases Cardiovascular Diseases Brain Infarction Brain Ischemia |
ClinicalTrials.gov processed this record on June 13, 2013